Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide access to paclitaxel therapy to subjects with
advanced or recurrent esophageal cancer who have completed the previous Phase 2 study
(CA139-540) and who should continue on therapy with paclitaxel as assessed by the treating
investigator(s). To evaluate the severity of observed adverse reactions in treated subjects
for assessment of long-term safety.